3D nanocomposites of β-TCP-H 3 BO 3 -Cu with improved mechanical and biological performances for bone regeneration applications.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Bone Regeneration*/drug effects ; Nanocomposites*/chemistry ; Calcium Phosphates*/chemistry ; Calcium Phosphates*/pharmacology ; Copper*/chemistry ; Copper*/pharmacology ; Anti-Bacterial Agents*/pharmacology ; Anti-Bacterial Agents*/chemistry; Animals ; Humans ; Porosity ; Osteoblasts/drug effects ; Biocompatible Materials/chemistry ; Biocompatible Materials/pharmacology ; Materials Testing ; Microbial Sensitivity Tests ; Cell Line ; Zebrafish

Recently, 3-D porous architecture of the composites play a key role in cell proliferation, bone regeneration, and anticancer activities. The osteoinductive and osteoconductive properties of β-TCP allow for the complete repair of numerous bone defects. Herein, β-TCP was synthesized by wet chemical precipitation route, and their 3-D porous composites with H 3 BO 3 and Cu nanoparticles were prepared by the solid-state reaction method with improved mechanical and biological performances. Several characterization techniques have been used to investigate the various characteristics of fabricated porous composites. SEM and TEM studies revealed the porous morphology and hexagonal sheets of the β-TCP for the composite THC8 (82TCP-10H 3 BO 3 -8Cu). Moreover, the mechanical study showed excellent compressive strength (188 MPa), a high Young's modulus (2.84 GPa), and elevated fracture toughness (9.11 MPa.m ^1/2 ). An in vitro study by MTT assay on osteoblast (MG-63) cells demonstrated no or minimal cytotoxicity at the higher concentration, 100 µg/ml after 24 h and it was found a more pronounced result at 20 µg/ml on increasing the concentration of Cu nanoparticles after incubating 72 h. The THC12 composite showed the highest antibacterial potency exclusively against B. subtilis. S. pyogene, S. typhi and E. coli. at 10 mg/ml, indicating its potential effectiveness in inhibiting all of these pathogens. Genotoxicity and cytotoxicity tests were also performed on rearing Drosophila melanogaster, and these findings did not detect any trypan blue-positive staining, which further recommended that the existence of composites did not harm the larval gut. Therefore, the fabricated porous composites THC8 and THC12 are suitable for bone regrowth without harming the surrounding cells and protect against bacterial infections.
Competing Interests: Declarations. Competing interests: The authors declare no competing interests.
(© 2025. The Author(s).)

Bioengineering (Basel). 2023 May 16;10(5):. (PMID: 37237667)
Chem Res Toxicol. 2023 Jun 19;36(6):926-933. (PMID: 37261822)
J Mater Sci Mater Med. 2010 Sep;21(9):2701-10. (PMID: 20644983)
Nat Commun. 2018 Apr 11;9(1):1397. (PMID: 29643347)
RSC Adv. 2019 Dec 11;9(70):40977-40996. (PMID: 35540076)
Adv Mater. 2014 Jul 16;26(27):4627-31. (PMID: 24890678)
Saudi J Biol Sci. 2018 Feb;25(2):361-366. (PMID: 29472791)
ACS Appl Mater Interfaces. 2022 Jan 12;14(1):978-989. (PMID: 34970910)
BMC Infect Dis. 2020 Sep 1;20(1):646. (PMID: 32873235)
Biomolecules. 2019 Apr 18;9(4):. (PMID: 31003561)
J Bacteriol. 2007 Mar;189(5):1616-26. (PMID: 17189367)
Int J Biol Macromol. 2020 Dec 15;165(Pt A):333-345. (PMID: 32980413)
J Am Chem Soc. 2005 Jul 6;127(26):9506-11. (PMID: 15984877)
Biol Trace Elem Res. 2015 Oct;167(2):264-71. (PMID: 25846213)
Expert Rev Med Devices. 2005 Jan;2(1):87-101. (PMID: 16293032)
Asian Pac J Cancer Prev. 2012;13(4):1617-20. (PMID: 22799377)
J Appl Crystallogr. 2021 Feb 14;54(Pt 2):661-672. (PMID: 33953659)
J Mech Behav Biomed Mater. 2023 Sep;145:106032. (PMID: 37506567)
Cancer Lett. 2004 Dec 8;216(1):21-9. (PMID: 15500945)
Sci Rep. 2020 Feb 6;10(1):2062. (PMID: 32029875)
Korean J Fam Med. 2018 Jan;39(1):2-9. (PMID: 29383205)
ACS Appl Mater Interfaces. 2019 Mar 27;11(12):11157-11166. (PMID: 30869853)
RSC Adv. 2019 Jan 7;9(2):781-789. (PMID: 35517622)
Acta Pol Pharm. 2011 Sep-Oct;68(5):687-92. (PMID: 21928713)
Dalton Trans. 2019 Dec 28;48(48):17810-17817. (PMID: 31773125)
Acta Biomater. 2009 Oct;5(8):3157-64. (PMID: 19435618)
Int J Bioprint. 2023 Jan 19;9(2):673. (PMID: 37065658)
Int J Pharm. 2023 Aug 25;643:123212. (PMID: 37429561)
J Craniomaxillofac Surg. 2012 Dec;40(8):706-18. (PMID: 22297272)
Sci Rep. 2013;3:2203. (PMID: 23857555)
Mater Sci Eng C Mater Biol Appl. 2021 Oct;129:112410. (PMID: 34579919)
Phys Chem Chem Phys. 2006 Jun 7;8(21):2464-72. (PMID: 16721430)
Acta Biomater. 2020 Sep 1;113:23-41. (PMID: 32565369)
ACS Biomater Sci Eng. 2024 Apr 8;10(4):2116-2132. (PMID: 38498674)
J Trace Elem Med Biol. 2021 Jan;63:126647. (PMID: 33010650)
Adv Microb Physiol. 2017;70:193-260. (PMID: 28528648)
Adv Mater. 2014 Aug 27;26(32):5646-52. (PMID: 24924258)
Front Microbiol. 2016 Jun 28;7:963. (PMID: 27446005)
Int J Nanomedicine. 2019 May 13;14:3491-3502. (PMID: 31190806)
Biomaterials. 1997 Oct;18(20):1339-47. (PMID: 9363333)
J Mater Chem B. 2020 Jul 8;8(26):5729-5744. (PMID: 32515763)
Int J Mol Sci. 2018 Mar 12;19(3):. (PMID: 29534546)
Toxicol In Vitro. 2023 Oct;92:105654. (PMID: 37495164)
Biomaterials. 2013 Sep;34(29):7117-26. (PMID: 23787109)
Indian J Orthop. 2019 Jan-Feb;53(1):82-88. (PMID: 30905986)
Dent Mater. 2012 Feb;28(2):113-22. (PMID: 22047943)
J Mass Spectrom. 2016 Sep;51(9):828-40. (PMID: 27476478)
Adv Drug Deliv Rev. 2012 Sep;64(12):1142-51. (PMID: 22664228)
Prostate. 2003 Jan 1;54(1):44-9. (PMID: 12481254)
J Mater Chem B. 2014 Dec 28;2(48):8547-8557. (PMID: 32262213)
Biomaterials. 2010 Mar;31(7):1465-85. (PMID: 19969343)
Biosens Bioelectron. 2018 Feb 15;100:304-311. (PMID: 28942213)
Acta Biomater. 2015 Sep;23:329-337. (PMID: 26004220)
J Appl Biomater. 1991 Fall;2(3):187-208. (PMID: 10149083)
Curr Biol. 2011 Nov 8;21(21):R877-83. (PMID: 22075424)
Clin Microbiol Infect. 2021 Jan;27(1):83-88. (PMID: 32745596)
Oncotarget. 2015 Feb 28;6(6):3553-62. (PMID: 25708684)
Chem Rev. 2021 Feb 10;121(3):1286-1424. (PMID: 33315388)
FASEB J. 2016 Nov;30(11):3887-3900. (PMID: 27511945)
Oral Maxillofac Surg. 2018 Dec;22(4):443-450. (PMID: 30345483)

Keywords: Antibacterial; Bone repair; Composites; In vitro-study; Mechanical performances; Morphology; β-tricalcium phosphate

0 (Calcium Phosphates)
0 (beta-tricalcium phosphate)
789U1901C5 (Copper)
0 (Anti-Bacterial Agents)
0 (Biocompatible Materials)

Date Created: 20250125 Date Completed: 20250125 Latest Revision: 20250130

20250130

PMC11763077

10.1038/s41598-025-87988-4

39863796